Advertisement

Reactions Weekly

, Volume 1765, Issue 1, pp 43–43 | Cite as

Antipsychotics

Metabolic Syndrome: case report
Case report
  • 63 Downloads

An adult [age at the time of first reaction onset not clearly stated] man developed metabolic syndrome (MS) during treatment with ziprasidone, risperidone, olanzapine, lurasidone and asenapine for schizoaffective disorder [routes and durations of treatments to reaction onset not stated; not all dosages stated].

The man had chronic psychosis, which had been earlier diagnosed to be schizophrenia. The diagnosis of psychosis had later been amended to schizoaffective disorder. Additionally, he exhibited tobacco use and alcohol abuse. He presented with his mother in August 2011 (at the age of 37 years) after unsatisfactory psychiatric treatment outcomes previously. He had a psychiatric history of 7 years, smoking marijuana daily for about 4 years in his late teens followed by two psychiatric hospitalisations; the first in 1998 (at the age of 1 year) and subsequently in 2000 (at the age of 19 years). From this point forward, he stopped marijuana use. He did not receive any psychiatric care...

Reference

  1. Halaris A, et al. Metabolic syndrome reversal with cariprazine. Journal of Clinical Psychopharmacology 39: 413-416, No. 4, Jul-Aug 2019. Available from: URL: http://doi.org/10.1097/JCP.0000000000001074 - USA

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations